Difflam

Phase 1Small molecule

UUniversity of Melbourne

Difflam is one of 36 small molecule programs targeting Respiratory tract infection. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

Respiratory Tract InfectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

80 competitors in Respiratory Tract Infection

#DrugCompanyPhaseTrials

Advil

KKenvue Brands

Approved

1 2

Paracetamol

GSK

Approved

2 3

Merrem

BB. Braun Medical Inc.

Approved

—4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Tamiflu

CConrado Roberto Hoffmann Filho

Phase 3

1 6

Veklury

Gilead

Phase 2

1 7

Quietus

Merck & Co.

Phase 2

1 8

Rapivab

BBioCryst Pharmaceuticals

Phase 3

1 9

Broncho-Vaxom

OOM Pharma SA

Phase 3

1 10

Pelubiprofen

Daewon Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory tract infection1 trial

Effect of Over-the-counter NSAIDS on Cough Reflex Sensitivity in Patients with Upper Respiratory Tract Infections

Completed·UUniversity of Melbourne·Phase 1·NCT05955885·101 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Difflam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Difflam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Difflam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Melbourne company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Melbourne

Difflam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory tract infection1 trial

References

Drug Info

Quick Facts

Related News